Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin

International Journal of Antimicrobial Agents

Volumn 30, Issue 6, 2007, Pages 551-554

  Madureira, Adrienne ^a   Bergeron, Anne ^a   Lacroix, Claire ^a   Robin, Marie ^a   Rocha, Vanderson ^a   de Latour, Régis Peffault ^a   Ferry, Christèle ^a   Devergie, Agnès ^a   Lapalu, Jordane ^a   Gluckman, Eliane ^a   Socié, Gérard ^a   Ghannoum, Mahmoud ^b   Ribaud, Patricia ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Aspergillosis; Breakthrough infections; Caspofungin; Transplantation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; PREDNISOLONE; STEROID; VORICONAZOLE;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CAUSE OF DEATH; CLINICAL ARTICLE; FEVER; GRAFT RECIPIENT; HUMAN; INCIDENCE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; SALVAGE THERAPY; SCHOOL CHILD; TREATMENT RESPONSE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 35748956729     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.07.026     Document Type: Article

References (15)

1. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
2. Ghannoum M.A., and Rice L.B. Antifungal agents: mode of action, mechanism of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12 (1999) 501-517
3. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 7-14
4. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. M38-A. Wayne, PA: CLSI; 2002.
5. Odds F.C., Motyl M., Andrade R., et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 42 (2004) 3475-3482
6. Pavie J., Lacroix C., Hermoso D.G., et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 43 (2005) 4902-4904
7. Martino R., and Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 132 (2006) 138-154
8. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 (2002) 225-234
9. Maertens J., Teppler H., Lupinacci R., Bourque M.R., DiNubile M.J., and Sable C. Empirical antifungal therapy (Rx) with caspofungin (CAS) vs liposomal amphotericin B (L-AmB) for persistently febrile neutropenic patients (Pts) with acute myeloid leukemia (AML). American Society of Haematology Annual Meeting. Blood 140 (2004) 1337
10. Mattiuzzi G.N., Alvarado G., Giles F.J., et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50 (2006) 143-147
11. Mougdal V., Little T., Boikov D., and Vazquez J.A. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49 (2005) 767-769
12. Candoni A., Mestroni R., Damiani D., et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 75 (2005) 227-233
13. Maertens J., Raad I., Petrikkos G., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
14. Betts R., Glasmacher A., Maertens J., et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 106 (2006) 466-473
15. Imhof A., Balajee S.A., Fredericks D.N., Englund J.A., and Marr K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39 (2004) 743-746